Literature DB >> 28444221

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Ann Dandurand, John Ouyang, Frank S Czerwiec, Jaime D Blais.   

Abstract

Entities:  

Year:  2017        PMID： 28444221     DOI： 10.1093/ndt/gfx079

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  19 in total

1.  Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD.

Authors:  Ao Li; Yuchen Xu; Song Fan; Jialin Meng; Xufeng Shen; Qian Xiao; Yuan Li; Li Zhang; Xiansheng Zhang; Guanqing Wu; Chaozhao Liang; Dianqing Wu
Journal:  JCI Insight       Date:  2018-03-08

2.  Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

Authors:  Reem A Mustafa; Alan S L Yu
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-13       Impact factor: 8.237

3.  Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

4.  Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Marie E Edwards; Fouad T Chebib; Maria V Irazabal; Troy G Ofstie; Lisa A Bungum; Andrew J Metzger; Sarah R Senum; Marie C Hogan; Ziad M El-Zoghby; Timothy L Kline; Peter C Harris; Frank S Czerwiec; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-19       Impact factor: 8.237

5.  Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.

Authors:  Yashang Lee; Katrina Lehmann Blount; Feng Dai; Siobhan Thompson; Jonathan Kaufman Scher; Sherrie Bitterman; Madeline Droher; Erica L Herzog; Gilbert Moeckel; Anil Karihaloo; Neera K Dahl
Journal:  Clin Exp Nephrol       Date:  2018-02-16       Impact factor: 2.801

Review 6.  A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Authors:  Fouad T Chebib; Ronald D Perrone; Arlene B Chapman; Neera K Dahl; Peter C Harris; Michal Mrug; Reem A Mustafa; Anjay Rastogi; Terry Watnick; Alan S L Yu; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2018-09-18       Impact factor: 10.121

7.  Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?

Authors:  Dipal M Patel; Neera K Dahl
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-29       Impact factor: 8.237

8.  Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.

Authors:  Olivier Devuyst; Arlene B Chapman; Susan E Shoaf; Frank S Czerwiec; Jaime D Blais
Journal:  Kidney Int Rep       Date:  2017-07-21

9.  Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Authors:  Emilie Cornec-Le Gall; Jaime D Blais; Maria V Irazabal; Olivier Devuyst; Ron T Gansevoort; Ron D Perrone; Arlene B Chapman; Frank S Czerwiec; John Ouyang; Christina M Heyer; Sarah R Senum; Yannick Le Meur; Vicente E Torres; Peter C Harris
Journal:  Nephrol Dial Transplant       Date:  2018-04-01       Impact factor: 5.992

10.  Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Riccardo Magistroni
Journal:  G Tec Nefrol Dial       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.